Closiver Solution for Injection for Sheep

Main information

  • Trade name:
  • CLOSAMECTINE SOLUTION INJECTABLE POUR OVINS
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CLOSAMECTINE SOLUTION INJECTABLE POUR OVINS
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ivermectin, combinations
  • Therapeutic area:
  • Sheep

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0277/002
  • Authorization date:
  • 26-05-2011
  • EU code:
  • UK/V/0277/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:May2011

AN:00041/2011

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

ClosiverSolutionforInjectionforSheep(UK&IE)

ClosamectinSolutionforInjectionforSheep(AT,BE,CZ,IT,ES&SK)

OestrocurSolutionforInjectionforSheep(FR)

ClosamectinFFSolutionforInjectionforSheep(PT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

ActiveSubstance(s)

Ivermectin 5mg/ml

Closantel(asclosantelsodiumdihydrate) 125mg/ml

OtherSubstances

Containssodiumformaldehydesulphoxylate5mg/ml(asantioxidant)

ForafulllistofexcipientsseeSection6.1

3. PHARMACEUTICALFORM

Solutionforinjection.

Aclearambersolution.

4. CLINICALPARTICULARS

4.1 TargetSpecies:

Sheep.

4.2 IndicationsforUse(SpecifyingtheTargetSpecies):

Forthetreatmentofmixedtrematode(fluke)andnematodeorarthropod

infestationsduetogastrointestinalroundworms,trematodes,lungworms,nasalbots

andmitesofsheep.

Gastrointestinalroundworms

Ostertagiacircumcincta(includinginhibitedL4),Ostertagiatrifurcata(adultandL4),

Haemonchuscontortus(includinginhibitedL4),Trichostrongylusaxei(adult),

Trichostrongyluscolubriformis(adultandL4),T.vitrinus(adult)Cooperiacurticei

(adultandL4),Oesophagostomumcolumbianum(adultandL4),O.venulosum

(adult)Chabertiaovina(adultandL4)Nematodirusfilicollis(adultandL4),Trichuris

ovis(adult).

[L4=fourthstagelarave]

Revised:May2011

AN:00041/2011

Lungworms

Dictyocaulusfilaria(adultand4 th stagelarvae)

Protostrongylusrufescens(adult)

LiverFluke(Adultsand7weeksimmature)

Fasciolagigantica,Fasciolahepatica

NasalBots

Oestrusovis

MangeMites

Psoroptesovis(Treatmentrequireasecondinjectionofanivermectin-onlyproduct

7dayslater.Seesections4.4and4.9)

Benzimidazole –resistantstrainsofHaemonchuscontortusandOstertagia

circumcinctaarealsocontrolled.

4.3 Contraindications:

Donotuseintravenouslyorintramuscularly.Avermectinsmaynotbewelltolerated

inallnon-targetspecies(casesofintolerancewithfataloutcomearereportedin

dogs –especiallyCollies,OldEnglishSheepdogsandrelatedbreedsorcrosses,

andalsointurtles/tortoises).

Donotuseincasesofknownhypersensitivitytotheactivesubstancesortoany

otherexcipients.

4.4 SpecialWarningsforEachTargetSpecies:

Careshouldbetakentoavoidthefollowingpracticesbecausetheyincreasethe

riskofdevelopmentofresistanceandcouldultimatelyresultinineffectivetherapy:

Toofrequentandrepeateduseofanthelminticsfromthesameclass,overan

extendedperiodoftime.

Underdosingwhichmaybeduetounderestimationofbodyweight,

misadministrationoftheproduct,orlackofcalibrationofthedosingdevice.

Suspectedclinicalcasesofresistancetoanthelminticsshouldbefurther

investigatedusingappropriatetests(e.g.FaecalEggCountReductionTest).

Wheretheresultsofthetestsstronglysuggestresistancetoaparticular

anthelmintic,ananthelminticbelongingtoanotherpharmacologicalclassand

havingadifferentmodeofactionshouldbeused.

ResistancetoivermectinandclosantelhasbeenreportedinHaemonchuscontortus

insheep.Thereforetheuseofthisproductshouldbebasedonlocal

epidemiologicalinformationaboutthesusceptibilityoftheHaemonchuscontortus

andrecommendationsonhowtolimitfurtherselectionforresistanceto

anthelmintics.

Insheeptreatmentofpsoropticmange(sheepscab)withoneinjectionofthis

productwillnotbeeffectiveineliminatingallthemites.Asuitableivermectin –only

Revised:May2011

AN:00041/2011

injectableproductmustbeadministeredsevendaysafterthetreatmentwiththis

producttotreatclinicalsignsandtoeliminatethemites.

Sheepscab(Psoroptesovis)isanextremelycontagiousexternalparasiteofsheep.

Toensurecompletecontrolgreatcaremustbetakentoavoidre-infestation,as

mitesmaybeviableforupto15daysoffthesheep.Itisimportantthatallsheep

whichhavebeenincontactwithinfectedsheeparetreatedwithanappropriate

product.Contactbetweentreated,infectedanduntreatedflocksmustbeavoided

untilatleastsevendaysaftertreatment.

4.5 SpecialPrecautionsforUse:

i. Specialprecautionsforuseinanimals

None

ii. Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Donotsmoke,eatordrinkwhilehandlingtheproduct.

Directcontactoftheproductwiththeskinshouldbekepttoaminimum.Wash

handsafteruse.Takecaretoavoidself-injection.Inadvertentself-injection

mayresultinlocalirritationand/orpainattheinjectionsite.

4.6 AdverseReactions(FrequencyandSeriousness):

Transitoryswellinghasoccasionallybeenobservedattheinjectionsite.

Occasionallythisswellingisaccompaniedbypainanddiscomfort.Thisswelling

resolvescompletelywithin14daysfollowingtreatment.

4.7 UseDuringPregnancy,LactationorLay:

ClosiverInjectioncanbeadministeredtosheepatanystageofpregnancyor

lactationprovidedthatthemilkisnotintendedforhumanconsumption.(See

section4.11).

4.8 InteractionswithOtherMedicamentsandOtherFormsofInteraction:

Donotadministerconcomitantlywithchlorinatedcompounds.TheeffectofGABA

agonistsareincreasedbyivermectin.

Pleaserefertosection4.3oftheSPC.

4.9 AmountstobeAdministeredandAdministrationRoute:

ClosiverInjectionshouldbeadministeredatadosagerateof200

givermectinper

kgbodyweightand5mgclosantelperkgbodyweight(1mlper25kg).Itshould

onlybeinjectedsubcutaneouslyintotheneck.Asterile16-gauge,one-inchneedle

isrecommended.

ForthetreatmentandcontrolofsheepscabaninjectionofClosiverInjectionfor

Sheepmaybeadministeredbutmustbefollowedwithasecondinjectionofan

ivermectinonlyproductsevendaysaftertheinitialinjectiontotreatclinicalsignsof

Revised:May2011

AN:00041/2011

scabandtoeliminatemites.Thisinjectionshouldbeadministeredattheotherside

oftheneck.

Thisproductdoesnotcontainanantimicrobialpreservative.Swabseptumbefore

removingeachdose.Useadrysterileneedleandsyringe.For250mland500ml

packsizes,useofamultipledosesyringeisrecommended.Torefillthesyringe,

useofadraw-offneedleisrecommendedtoavoidexcessivebroachingofthe

stopper.

Donotexceed40broachingspervial.Ifmorethan40broachingsarerequired,use

ofadrawoffneedleisrecommended.

Thetimingfortreatmentshouldbebasedonepidemiologicalfactorsandshouldbe

customisedforeachindividualfarm.Aswithotheranthelmintics,veterinaryadvice

shouldbesoughtonappropriatedosingprogrammesandstockmanagementto

achieveadequateparasitecontrolandreducethelikelihoodofresistance

developing.

Toensureadministrationofacorrectdose,bodyweightshouldbedeterminedas

accuratelyaspossible;accuracyofthedosingdeviceshouldbechecked.

Ifanimalsaretobetreatedcollectivelyratherthanindividuallytheyshouldbe

groupedaccordingtotheirbodyweightanddosedaccordingly,inordertoavoid

under-orover-dosing.

4.10Overdose(Symptoms,EmergencyProceduresandAntidotes)(ifnecessary):

Doselevelsupto4.0mg/kgivermectin(20timestherecommendeddosage)

administeredsubcutaneously,resultinataxiaanddepressioninsheep.

Closantellikeothersalicylanilidesisapotentuncouplerofoxidativephosphorylation

andthesafetyindexisnotashighasisthecaseofmanyotheranthelmintics.

Howeverwhereusedasdirectedthereareunlikelytobeanyuntowardeffects.

Signsofoverdosagecanincludelossofappetite,decreasedvision,loosefaeces

andincreasedfrequencyofdefaecation.Highdosesmaycauseblindness,

hyperventilation,hyperthermia,generalweakness,inco-ordination,convulsions,

tachycardiaandinextremecasesdeath.Thelethaldose(LD

)ofclosantelin

sheep,afterasingleintramusculardose,washigherthan40mg/kg.Moreover,

somestudiesconductedinsheepreportedsignsofoverdosewithdosesofaround

4timesthetherapeuticdose(bothinjectableandoral).Treatmentofoverdosageis

symptomaticasnoantidotehasbeenidentified.

4.11WithdrawalPeriod:

Meatandoffal: 28days

Milk:Notpermittedforuseinanimalsproducingmilkforhumanconsumption,

includingpregnantanimalsintendedtoproducemilkforhumanconsumption.

Revised:May2011

AN:00041/2011

5. PHARMACOLOGICALPROPERTIES

ATCvetcode:QP54AA51

Pharmacotherapeuticgroup:Endectocides

5.1 PharmacodynamicProperties:

Ivermectinisanendectocidewithactivityagainstawiderangeofinternaland

externalparasites.Ivermectinisamacrocyliclactoneandactsbyinhibitingnerve

impulses.Itbindsselectivelyandwithhighaffinitytoglutamate-gatedchlorideion

channelswhichoccurininvertebratenerveandmusclecells.Thisleadstoan

increaseinthepermeabilityofthecellmembranetochlorideionswith

hyperpolarizationofthenerveormusclecell,resultinginparalysisanddeathofthe

relevantparasites.Compoundsofthisclassmayalsointeractwithotherligand-

gatedchloridechannels,suchasthosegatedbytheneurotransmittergamma-

aminobutyricacid(GABA).Themarginofsafetyforcompoundsofthisclassis

attributabletothefactthatmammalsdonothaveglutamate-gatedchloride

channels.Themacrocyliclactoneshavealowaffinityforothermammalianligand-

gatedchloridechannelsandtheydonotreadilycrosstheblood-brainbarrier.

Closantelisamemberofthesalicylanilideclassofanthelmintics.Salicylanilides

arehydrogen(proton)ionophores(referredtoasoxidativephosphorylase

uncouplers.)

Thechemicalstructureofsalicylanilidesillustratethepossessionofadetachable

proton.Thistypeofmoleculeislipophilicandisknowntoshuttleprotonsacross

membranes,inparticulartheinnermitochondrialmembrane.Closantelactsby

uncouplingoxidativephosphorylation.

Closantelisaparasiticidewithflukicideactivityandefficacyagainstcertainother

helminthsandarthropods.

5.2 PharmacokineticProperties:

AftersubcutaneousadministrationofClosiverInjectiontosheepatadoserateof

givermectinperkgand5mgclosantelperkgthefollowingparameterswere

observed:IvermectinCmaxof24.52ng/mlandAUCof2082.93ng.h/ml;

ClosantelCmaxof70.4

g/mlandAUCof41043

g.h/ml.

Ivermectinbindsextensivelytoplasmaproteins.Duetoitshighlipophilicnature,

ivermectinisextensivelydistributed.Ittendstoaccumulateinfattissue,whichacts

asadrugreservoirandthehighestlevelsofivermectinarefoundinliverandfat.

Ivermectinisonlypartiallymetabolised.Ivermectinismainlyeliminatedinthe

faecesasunaltereddrugandfaecalexcretionaccountsfor90%ofthedose

administeredwith<2%ofthedoseexcretedinurine.Ivermectinisalsoexcretedby

themammarygland.

Salicylanilidesarepoorlymetabolisedandareexcretedmainlyunchanged.The

mainexcretionrouteisthefaecesviathebile.Closantelisextensivelyboundto

Revised:May2011

AN:00041/2011

plasmaproteins,almostexclusivelytoalbumin.Thedistributiontotissuesispoor.

Closantelhasalongeliminationhalf-life.

6. PHARMACEUTICALPARTICULARS

6.1 ListofExcipients:

PovidoneK12

SodiumFormaldehydeSulphoxylate

Macrogol200

GlycerolFormal

6.2 MajorIncompatibilities:

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnot

bemixedwithotherveterinarymedicinalproducts.

6.3 Shelf-Life:

Shelf-lifeoftheveterinaryproductaspackagedforsale:18months.

Shelf-lifeafterfirstopeningofimmediatepackaging:28days.

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25°C.

Protectfromlight.

Discardunusedmaterial.

6.5 NatureandCompositionofImmediatePackaging:

100ml,250mland500mlTypeIglassmultidosevialsandaluminiumcaps

completewithbromobutylbungsandaluminiumseals.

Notallpacksizesmaybemarketed.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinalProduct

orWasteMaterialsDerivedfromtheUseofSuchProducts,ifappropriate:

EXTREMELYDANGEROUSTOFISHANDAQUATICLIFE.Donotcontaminate

surfacewatersorditcheswiththeproductorusedcontainer.Anyunusedproduct

orwastematerialsderivedfromsuchveterinarymedicinalproductsshouldbe

disposedofinaccordancewithlocalrequirements.

Revised:May2011

AN:00041/2011

7. MARKETINGAUTHORISATIONHOLDER

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

Newry

CoDown,BT356JP

NorthernIreland

8 MARKETINGAUTHORISATIONNUMBER

Vm 02000/4298

9. DATEOFFIRSTAUTHORISATION

01October2010

10. DATEOFREVISIONOFTHETEXT

May2011

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

There are no news related to this product.